Key facts
as of Sep 2026- Element Biosciences’s last known valuation is $1.0B.
- It has raised $683.3M across 2 recorded rounds; the latest was Later Stage VC (Series D) ($277.0M) in Jul 2024.
- Notable investors include Fidelity Management & Research Company, RA Capital Management, CONNECT(San Diego), Alexandria Venture Investments, Venrock — 15 tracked in total.
- 3 institutional filers report fund marks on Element Biosciences across 35 filings.
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Element Biosciences
Recorded secondary trades
No secondary trades in Element Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
3 filers · latest Jun 20263 SEC-registered funds reported 35 fair-value marks on Element Biosciences between Apr 2025 and Jun 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
2 roundsAbout Element Biosciences
Developer of genetic analysis tools intended to be used for the research and diagnostic markets. The company's technology develops a modular and high-performing DNA sequencing platform that will deliver quality data, workflow flexibility, and make next-generation sequencing technology more accessible, enabling medical researchers to benefit from and improve their research.
- Industry
- Other Healthcare Technology Systems
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2017
- Employees
- 407
- Website
- elementbiosciences.com/
- Ownership
- Privately Held (backing)